Birth control vaccine targeting leukemia inhibitory factor.

Area of Science:

• Reproductive Biology
• Immunology
• Vaccine Development

Background:

• Unintended pregnancies and elective abortions present significant public health challenges, necessitating improved contraceptive methods.
• Immunocontraception offers a promising alternative for an ideal contraceptive, with various targets under investigation.
• Leukemia Inhibitory Factor (LIF) is crucial for embryo development and implantation in mammals.

Purpose of the Study:

• To evaluate Leukemia Inhibitory Factor (LIF) and LIF-receptor (LIF-R) as potential targets for a novel birth control vaccine.
• To synthesize peptides from key binding regions of LIF and LIF-R and assess their immunogenic and contraceptive potential.

Main Methods:

• Peptides were synthesized based on sequences from LIF and LIF-receptor (LIF-R) involved in ligand-receptor binding.
• Antibodies against these peptides were generated and tested for their ability to neutralize LIF bioactivity in vitro.
• Peptide-based vaccines were created by conjugating peptides to carrier proteins and administered to female mice.

Main Results:

• Antibodies raised against the synthesized peptides demonstrated reduced LIF bioactivity in vitro.
• Immunization of female mice with peptide vaccines induced a sustained antibody response in the circulation and reproductive tract.
• All vaccine groups showed a significant inhibition of fertility, with LIF-R peptide vaccines proving more effective.

Conclusions:

• LIF and LIF-R represent a highly effective target for the development of an immunocontraceptive vaccine.
• This study provides the first evidence for LIF/LIF-R as a target for immunocontraception.
• The findings are translatable to humans, as LIF/LIF-R plays a vital role in human implantation and pregnancy.